Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) ("Erasca" or the "Company") breached their fiduciary duties owed to the Company and its shareholders.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.

The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

What Is the Investigation About?

According to a recently filed federal securities class action, investors allege that Erasca made materially misleading statements and omissions concerning ERAS-0015.

Among other things, the complaint alleges that:

• Erasca publicly promoted ERAS-0015 as a potential "best-in-class" therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines' RMC-6236;
• the Company's public disclosures allegedly relied upon improper comparisons to RMC-6236;
• Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures;
• investors allegedly were not adequately informed of those risks; and
• certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis.

April 2026 Disclosures

On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236.

Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited.

Following these disclosures, Erasca's share price experienced a substantial decline.

Potential Corporate Governance and Fiduciary Duty Issues

Grabar Law Office is investigating whether Erasca's directors and officers:

• caused or permitted the Company to issue materially misleading statements concerning ERAS-0015;
• failed to maintain adequate internal controls and disclosure controls;
• failed to properly monitor intellectual property, patent, trade secret, and competitive-risk issues;
• failed to ensure that comparative statements regarding ERAS-0015 were appropriately supported and disclosed;
• exposed the Company to litigation, regulatory, reputational, and financial harm; and
• breached fiduciary duties owed to Erasca and its shareholders.

Shareholders May Have Legal Rights

If you are a current Erasca shareholder what has held shares since prior to January 14, 2025, you may have the ability to seek corporate governance reforms, damages on behalf of the Company, and other relief through a shareholder derivative action including a court approved incentive award.

Derivative actions differ from securities class actions because they seek recovery for the benefit of the corporation itself and may pursue claims against directors, officers, and other fiduciaries whose conduct allegedly harmed the company.

Contact Grabar Law Office

If you currently own Erasca common stock and would like to learn more about this investigation, please contact us:

Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, Pennsylvania 19103

Phone: 267-507-6085
Email: jgrabar@grabarlaw.com

Attorney Advertising. Prior results do not guarantee a similar outcome